what are the risks of glp 1 How Do You Know When Semaglutide GLP-1 Is Working? GLP-1 Safety Check - National

Clinical trials of tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor agonist, reported constipation in approximately 2527% of participants at therapeutic doses

Clinical trials have demonstrated the effectiveness of Semaglutide GLP-1 in promoting significant weight loss

It is important for patients to rotate the injection site to avoid discomfort at the injection site

The article describes TSH monitoring roughly every 6 to 12 weeks during the first six months of GLP-1 therapy, then annually

Skin cancer A 2025 review found that using Melanotan II could lead to the development of skin cancer, such as malignant melanoma

Of note is the number of patients involved in this post-hoc analysis, unlike the small populations analysed in the other studies of this neurological field